Jury Clears Armistice Capital in Vaxart 'Pump-and-Dump' Lawsuit

SAN FRANCISCO, CA – May 14, 2026 – A federal jury delivered a swift and decisive victory for Armistice Capital LLC, completely exonerating the hedge fund and two of its top executives of securities fraud and insider trading. The verdict, reached after less than four hours of deliberation, concludes a high-stakes, two-week trial that scrutinized the firm's lucrative stock sales during the frenzied race for a COVID-19 vaccine.

The case centered on allegations that Armistice, its founder Steven Boyd, and Managing Director Keith Maher orchestrated a "pump-and-dump" scheme, manipulating the stock of biotech firm Vaxart Inc. in the summer of 2020. A class of investors claimed the hedge fund used misleading Vaxart press releases about its involvement in the U.S. government's "Operation Warp Speed" to artificially inflate the share price before cashing out for an estimated $200 million profit.

The full defense verdict, handed down Tuesday in the U.S. District Court for the Northern District of California, represents a significant vindication for Armistice after six years under a cloud of litigation. It also serves as a stark reminder of the high bar plaintiffs face in proving fraud against sophisticated investors in the volatile public markets.

The Pandemic-Era Lawsuit

The legal battle's origins trace back to June 2020, a period of intense market speculation around companies involved in COVID-19 solutions. Vaxart, a small biotech firm developing an oral vaccine tablet, saw its stock price skyrocket on the back of two key announcements.

On June 25, 2020, Vaxart announced a deal that would supposedly enable the production of "a billion or more" vaccine doses. The very next day, on June 26, the company issued a press release titled "Vaxart's COVID-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." Vaxart’s stock surged over 90% on the news.

Plaintiffs argued these announcements were profoundly misleading. They contended the manufacturing partner lacked the capacity for billion-dose production and, more critically, that the Operation Warp Speed announcement created the false impression that Vaxart was a primary candidate receiving significant federal funding. In reality, its selection was for a preliminary, government-funded study in non-human primates, a far more limited role than the headline suggested.

In the days following these announcements, Armistice Capital, which had become a majority owner of Vaxart in 2019, sold more than 27 million shares. Investors who bought the stock at its peak suffered heavy losses when the full details of Vaxart's limited OWS involvement became clearer, and the company later disclosed it was under investigation by the SEC and federal prosecutors.

A Tale of Two Defenses

The case presented a fascinating split in legal strategy. Vaxart and its executives, who were originally named as co-defendants and were responsible for issuing the press releases, chose to settle the claims against them in 2022 for $12 million. By settling, the company avoided the risk and expense of a jury trial, particularly after a judge had already sustained claims that its statements could be seen as materially misleading.

Armistice Capital, however, chose a different path. Represented by a team from Akin Gump Strauss Hauer & Feld LLP, the hedge fund and its executives decided to fight the allegations in court, betting that a jury would distinguish their actions as an investor from the company's own public disclosures. Their decision to proceed to trial was a high-risk, high-reward strategy, as securities class actions rarely reach a jury, with most ending in settlements to avoid the uncertainty of a verdict. This divergence set the stage for a courtroom drama that would ultimately test the very definition of market manipulation.

Dissecting the Defense: Beyond the Headlines

At trial, Armistice's defense team methodically dismantled the plaintiffs' narrative. Their core argument was not that the headlines were perfect, but that the full press releases were technically accurate and that Armistice had no hand in creating them.

Defense counsel Charles Connolly of Akin Gump argued that the plaintiffs' entire case was built on "isolated phrases rather than the full content of the Vaxart press releases." The defense successfully showed that Armistice, Boyd, and Maher had no involvement in drafting, editing, or approving the announcements. They proved that the fund, like the rest of the public, only learned of the news after the releases were issued, a key point that neutralized the insider trading allegations.

A central theme of the defense, which appeared to resonate strongly with the jury, was the concept of investor responsibility. "A reasonable investor does not just read the headlines," Connolly argued during the trial. This line of reasoning shifted focus toward the expectation that investors should perform their own due diligence, especially in a hyper-volatile market driven by pandemic news, rather than relying on superficial interpretations of company announcements. The defense contended that Armistice's trading was consistent with its investment strategy and not part of a fraudulent scheme.

The jury's swift verdict, clearing the defendants on all counts, suggests they accepted the argument that there was no evidence of fraudulent intent or a coordinated scheme to deceive the market.

Vindication and the Road Ahead

For Armistice Capital, the verdict is more than just a legal win; it is a powerful public exoneration. After years of facing serious allegations that strike at the heart of a financial firm's integrity, the jury's decision provides a clean slate. The outcome is expected to bolster confidence among the firm's current and prospective investors, removing the significant reputational and financial overhang of the litigation.

The case's conclusion is significant for the broader financial and legal industries. Defense verdicts in securities class action trials are rare, and this outcome could embolden other institutional investors to challenge allegations they believe are meritless, rather than succumbing to the pressure of a costly settlement. It highlights the critical difference between a company making a misleading statement and an investor trading on that publicly available information.

The verdict reinforces the high standard of proof required to establish scienter—the intent to defraud—which remains one of the biggest hurdles for plaintiffs in securities litigation. While the Vaxart saga exposed the dangers of corporate hype during a public health crisis, the trial's conclusion ultimately placed the burden of proof on the accusers, who in the end failed to convince a jury that Armistice Capital had crossed the line from aggressive investing into outright fraud.